Incidence of tissue toxicities in gamma ray and fission neutron-exposed mice treated with Amifostine

David Paunesku, Tatjana Paunesku, Andrew Wahl, Yasushi Kataoka, Jeffrey Murley, David J. Grdina, Gayle E. Woloschak

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To determine the effects of Amifostine or WR-151327 on the incidence of lethal and non-lethal toxicities in a large cohort of mice exposed to γ-ray or fission-spectrum neutron radiation. Methods: To analyze data from 4000 B6CF1 mice which received a single whole body irradiation (WBI) with 206 cGy or 417 cGy cobalt-60 gamma rays or 10 cGy or 40 cGy of fission-spectrum neutrons (average energy 0.85 MeV) produced by the Janus reactor at Argonne National Laboratory. In the neutron cohort, Amifostine, WR-151327, saline or nothing was injected once, intraperitoneally, 30 minutes before irradiation. In the cobalt-60 cohort, WR-151327 was omitted from the same protocol. At the time of natural death, tissue toxicities found in these mice were recorded, and these records were analyzed. While all previous studies focused on the modulation of life shortening effects of WBI by Amifostine, in this study we calculated changes in the frequencies of 59 tissue toxicities and changes in the total number of toxicities per animal. Results: Amifostine protected against specific non-tumor pathological complications (67% of the non-tumor toxicities induced by gamma irradiation, 31% of the neutron induced specific toxicities), as well as specific tumors (56% of the tumor toxicities induced by gamma irradiation, 25% of the neutron induced tumors). Amifostine also reduced the total number of toxicities per animal for both genders in the gamma ray exposed mice and in males in the neutron exposed mice. Conclusions: Amifostine was protective against many, but not all, tissue toxicities caused by WBI gamma and neutron irradiation.

Original languageEnglish (US)
Pages (from-to)623-634
Number of pages12
JournalInternational Journal of Radiation Biology
Volume84
Issue number8
DOIs
StatePublished - Aug 4 2008

Fingerprint

Amifostine
Gamma Rays
Neutrons
toxicity
Gamma rays
gamma radiation
fission
mice
Toxicity
incidence
gamma rays
Tissue
neutrons
Incidence
Whole-Body Irradiation
Irradiation
irradiation
cobalt 60
Cobalt
Tumors

Keywords

  • Amifostine
  • Fission neutron and gamma-ray irradiation
  • Late tissue toxicity

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

Incidence of tissue toxicities in gamma ray and fission neutron-exposed mice treated with Amifostine. / Paunesku, David; Paunesku, Tatjana; Wahl, Andrew; Kataoka, Yasushi; Murley, Jeffrey; Grdina, David J.; Woloschak, Gayle E.

In: International Journal of Radiation Biology, Vol. 84, No. 8, 04.08.2008, p. 623-634.

Research output: Contribution to journalArticle

Paunesku, David ; Paunesku, Tatjana ; Wahl, Andrew ; Kataoka, Yasushi ; Murley, Jeffrey ; Grdina, David J. ; Woloschak, Gayle E. / Incidence of tissue toxicities in gamma ray and fission neutron-exposed mice treated with Amifostine. In: International Journal of Radiation Biology. 2008 ; Vol. 84, No. 8. pp. 623-634.
@article{986bb3ea667e49d6875abd39a573fa54,
title = "Incidence of tissue toxicities in gamma ray and fission neutron-exposed mice treated with Amifostine",
abstract = "Purpose: To determine the effects of Amifostine or WR-151327 on the incidence of lethal and non-lethal toxicities in a large cohort of mice exposed to γ-ray or fission-spectrum neutron radiation. Methods: To analyze data from 4000 B6CF1 mice which received a single whole body irradiation (WBI) with 206 cGy or 417 cGy cobalt-60 gamma rays or 10 cGy or 40 cGy of fission-spectrum neutrons (average energy 0.85 MeV) produced by the Janus reactor at Argonne National Laboratory. In the neutron cohort, Amifostine, WR-151327, saline or nothing was injected once, intraperitoneally, 30 minutes before irradiation. In the cobalt-60 cohort, WR-151327 was omitted from the same protocol. At the time of natural death, tissue toxicities found in these mice were recorded, and these records were analyzed. While all previous studies focused on the modulation of life shortening effects of WBI by Amifostine, in this study we calculated changes in the frequencies of 59 tissue toxicities and changes in the total number of toxicities per animal. Results: Amifostine protected against specific non-tumor pathological complications (67{\%} of the non-tumor toxicities induced by gamma irradiation, 31{\%} of the neutron induced specific toxicities), as well as specific tumors (56{\%} of the tumor toxicities induced by gamma irradiation, 25{\%} of the neutron induced tumors). Amifostine also reduced the total number of toxicities per animal for both genders in the gamma ray exposed mice and in males in the neutron exposed mice. Conclusions: Amifostine was protective against many, but not all, tissue toxicities caused by WBI gamma and neutron irradiation.",
keywords = "Amifostine, Fission neutron and gamma-ray irradiation, Late tissue toxicity",
author = "David Paunesku and Tatjana Paunesku and Andrew Wahl and Yasushi Kataoka and Jeffrey Murley and Grdina, {David J.} and Woloschak, {Gayle E.}",
year = "2008",
month = "8",
day = "4",
doi = "10.1080/09553000802241762",
language = "English (US)",
volume = "84",
pages = "623--634",
journal = "International Journal of Radiation Biology",
issn = "0955-3002",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Incidence of tissue toxicities in gamma ray and fission neutron-exposed mice treated with Amifostine

AU - Paunesku, David

AU - Paunesku, Tatjana

AU - Wahl, Andrew

AU - Kataoka, Yasushi

AU - Murley, Jeffrey

AU - Grdina, David J.

AU - Woloschak, Gayle E.

PY - 2008/8/4

Y1 - 2008/8/4

N2 - Purpose: To determine the effects of Amifostine or WR-151327 on the incidence of lethal and non-lethal toxicities in a large cohort of mice exposed to γ-ray or fission-spectrum neutron radiation. Methods: To analyze data from 4000 B6CF1 mice which received a single whole body irradiation (WBI) with 206 cGy or 417 cGy cobalt-60 gamma rays or 10 cGy or 40 cGy of fission-spectrum neutrons (average energy 0.85 MeV) produced by the Janus reactor at Argonne National Laboratory. In the neutron cohort, Amifostine, WR-151327, saline or nothing was injected once, intraperitoneally, 30 minutes before irradiation. In the cobalt-60 cohort, WR-151327 was omitted from the same protocol. At the time of natural death, tissue toxicities found in these mice were recorded, and these records were analyzed. While all previous studies focused on the modulation of life shortening effects of WBI by Amifostine, in this study we calculated changes in the frequencies of 59 tissue toxicities and changes in the total number of toxicities per animal. Results: Amifostine protected against specific non-tumor pathological complications (67% of the non-tumor toxicities induced by gamma irradiation, 31% of the neutron induced specific toxicities), as well as specific tumors (56% of the tumor toxicities induced by gamma irradiation, 25% of the neutron induced tumors). Amifostine also reduced the total number of toxicities per animal for both genders in the gamma ray exposed mice and in males in the neutron exposed mice. Conclusions: Amifostine was protective against many, but not all, tissue toxicities caused by WBI gamma and neutron irradiation.

AB - Purpose: To determine the effects of Amifostine or WR-151327 on the incidence of lethal and non-lethal toxicities in a large cohort of mice exposed to γ-ray or fission-spectrum neutron radiation. Methods: To analyze data from 4000 B6CF1 mice which received a single whole body irradiation (WBI) with 206 cGy or 417 cGy cobalt-60 gamma rays or 10 cGy or 40 cGy of fission-spectrum neutrons (average energy 0.85 MeV) produced by the Janus reactor at Argonne National Laboratory. In the neutron cohort, Amifostine, WR-151327, saline or nothing was injected once, intraperitoneally, 30 minutes before irradiation. In the cobalt-60 cohort, WR-151327 was omitted from the same protocol. At the time of natural death, tissue toxicities found in these mice were recorded, and these records were analyzed. While all previous studies focused on the modulation of life shortening effects of WBI by Amifostine, in this study we calculated changes in the frequencies of 59 tissue toxicities and changes in the total number of toxicities per animal. Results: Amifostine protected against specific non-tumor pathological complications (67% of the non-tumor toxicities induced by gamma irradiation, 31% of the neutron induced specific toxicities), as well as specific tumors (56% of the tumor toxicities induced by gamma irradiation, 25% of the neutron induced tumors). Amifostine also reduced the total number of toxicities per animal for both genders in the gamma ray exposed mice and in males in the neutron exposed mice. Conclusions: Amifostine was protective against many, but not all, tissue toxicities caused by WBI gamma and neutron irradiation.

KW - Amifostine

KW - Fission neutron and gamma-ray irradiation

KW - Late tissue toxicity

UR - http://www.scopus.com/inward/record.url?scp=48249127986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249127986&partnerID=8YFLogxK

U2 - 10.1080/09553000802241762

DO - 10.1080/09553000802241762

M3 - Article

C2 - 18661379

AN - SCOPUS:48249127986

VL - 84

SP - 623

EP - 634

JO - International Journal of Radiation Biology

JF - International Journal of Radiation Biology

SN - 0955-3002

IS - 8

ER -